Designing a Clinical Trial to Evaluate the Safety and Efficacy of Oral Soraprazan in Stargardt Disease

Carel Hoyng¹, Andrew Lotery², Katarina Stingl³, Camiel Boon⁴, Maurizio Parodi⁵, Patty Dhooge⁴, Toby Peters⁶, Wolfgang Klein⁷, Mario Fsadni⁷, Marcus Müller⁹, Oliver Jungmann⁹

¹Department of Ophthalmology, Radboudumc, Netherlands, ²University of Southampton, United Kingdom, ³Center for Ophthalmology, University of Tübingen, Germany, ⁴Academic Hospital Leiden, Netherlands, ⁵Ospedale San Raffaele SRL, Italy, ⁶Donders Institute for Brain, Cognition and Behaviour, Netherlands, ⁷Katairio GmbH, Germany, ⁸International Pharm-Med Ltd, United Kingdom, ⁹Smerud Medical Research, Germany

Background

- Soraprazan has been reported in pre-clinical studies¹-⁵ to remove lipofuscin from RPE-cells, one of the hallmarks in the pathogenesis of Stargardt disease (STGD1)

Methods

- International consortium was formed
  - 5 investigator sites
  - Contract Research Organization
  - Start-up company & Sponsor
- A draft protocol and a business plan were fully costed and timelines defined. An application was filed with Horizon 2020.

Results

- This project has received funding of €5.8m from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779317
- Protocol for a randomized, proof of concept, double-masked, placebo-controlled, two arm, multicenter trial
  - 90 patients
  - 12 months
  - 20 milligrams, orally, once a day
  - Randomization 2:1

Primary variable: Change in qAF8 score from baseline to end of treatment (EoT) for soraprazan compared to placebo treated subjects.

Aim:
Start a phase II trial to evaluate the efficacy of soraprazan in reducing the amount of lipofuscin in RPE cells of subjects with STGD1

Conclusion

Soraprazan is potentially a new therapy for STGD1 which removes lipofuscin from RPE cells, thereby preventing or slowing disease progression.

A phase II trial will be conducted to evaluate the safety and efficacy of oral soraprazan in STGD1. Patient enrollment will be completed in 2019.

References


Contact:
Prof. Dr. Carel Hoyng
Carel.Hoyng@radboudumc.nl
Radboud university medical center

Disclosure:  Carel Hoyng: N; Andrew Lotery: N; Katarina Stingl: N; Camiel Boon: N; Maurizio Parodi: N; Patty Dhooge: N; Tobias Peters: N; Wolfgang Klein: I, C, F, S; Mario Fsadni: C; Hans Müller: E; Oliver Jungmann: E.